Results 241 to 250 of about 958,101 (344)

Status of hepatitis B virus and hepatitis C elimination in Singapore: a call for action. [PDF]

Singapore Med J
Wong YJ, Huang D.
europepmc   +1 more source

Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants

, 1992
Shiu‐Wan Chan, F. McOmish, Edward C. Holmes, B. C. Dow, J F Peutherer, E. A. C. Follett, P.L. Yap, Peter Simmonds   +7 more
openalex   +1 more source

Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea

British Journal of Clinical Pharmacology, EarlyView.
Aims Demographics and kidney function contribute to variability in lamivudine and tenofovir drug concentrations. The aim was to assess, for the first time, the pharmacokinetic variability of lamivudine and tenofovir in Papua New Guinean (PNG) HIV/AIDS patients.
Natália Bordin Andriguetti, Daniel Thomas Barratt, Joseph Tucci, Paul Pumuye, Andrew Alexander Somogyi   +4 more
wiley   +1 more source

Progress Toward Hepatitis C Virus Elimination among People Living with HIV-Hepatitis C Virus Coinfection in Canada. [PDF]

Can Liver J
El Sheikh MZ, Young J, Panagiotoglou D, Cooper C, Cox J, Martel-Laferrière V, Walmsley S, Klein MB.   +7 more
europepmc   +1 more source

Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder

British Journal of Clinical Pharmacology, EarlyView.
Aims Insomnia is a common sleep disorder, affecting up to 20% of the world population and adversely impacting productivity, health, and overall well‐being. Although pharmacologic options exist to treat insomnia, the health‐related quality of life for patients who are prescribed hypnotics is no higher than for those who are not, revealing a significant ...
Garth T. Whiteside, Ellie He, S. Shet Manjunath, Mingyan Zhou, Maha Ahmad, Stephen C. Harris   +5 more
wiley   +1 more source

The diagnostic value of decreased levels of inflammatory markers for the state of hepatitis C virus (HCV) infection. [PDF]

PLoS One
Han L, Bi L, Li X.
europepmc   +1 more source

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

British Journal of Clinical Pharmacology, EarlyView.
Aim Concomitant treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) is complicated by drug‐drug interactions (DDI). This analysis aimed to characterize the DDI between ritonavir‐boosted atazanavir (ATV/r) and rifampicin in plasma and peripheral blood mononuclear cells (PBMC).
Allan Kengo, Juan Eduardo Resendiz‐Galvan, Letisha Najjemba, Henry Mugerwa, Amedeo De Nicolò, Antonio D'Avolio, Shakir Atoyebi, Lubbe Wiesner, Elin M. Svensson, Catriona Waitt, Paolo Denti   +10 more
wiley   +1 more source

Cost-Effectiveness of Hepatitis C Virus Case Finding and Treatment in Eastern Europe and Central Asia. [PDF]

Liver Int
Walker JG, Schumacher IT, Trickey A, Vickerman P.   +3 more
europepmc   +1 more source

Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections

, 1993
Kenneth E. Sherman, Julia O’Brien, A G Gutierrez, Shannon M. Harrison, M S Urdea, Paul Neuwald, Judith C. Wilber   +6 more
openalex   +1 more source

Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses.
Eleanor G. Dixon, Evita Biraua, Edvards Brencsēns, Vitālijs Pašuks, Vija Riekstina, Anete Šperberga, Marisa D. Muckian, James W. Dear, Liga Kuksa, Derek J. Sloan, Helen R. Stagg   +10 more
wiley   +1 more source